File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1007/s12105-012-0364-5
- Scopus: eid_2-s2.0-84864138332
- PMID: 22782228
- WOS: WOS:000214599800011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer
Title | Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer |
---|---|
Authors | |
Keywords | Chemotherapy HPV/OPSCC Radiation |
Issue Date | 2012 |
Citation | Head and Neck Pathology, 2012, v. 6 n. SUPPL. 1, p. 91-97 How to Cite? |
Abstract | The incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC. © 2012 Springer Science+Business Media, LLC. |
Persistent Identifier | http://hdl.handle.net/10722/194431 |
ISSN | 2023 Impact Factor: 3.2 2023 SCImago Journal Rankings: 0.890 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lui, VWY | - |
dc.contributor.author | Grandis, JR | - |
dc.date.accessioned | 2014-01-30T03:32:35Z | - |
dc.date.available | 2014-01-30T03:32:35Z | - |
dc.date.issued | 2012 | - |
dc.identifier.citation | Head and Neck Pathology, 2012, v. 6 n. SUPPL. 1, p. 91-97 | - |
dc.identifier.issn | 1936-055X | - |
dc.identifier.uri | http://hdl.handle.net/10722/194431 | - |
dc.description.abstract | The incidence of human papillomavirus-positive oropharyngeal cancer (HPV/OPSCC) is rapidly increasing, which will represent a major public health burden for decades to come. Although HPV/OPSCC is generally associated with a better prognosis than HPV-negative OPSCC, the survival rate of individuals with higher-risk clinical and pathologic features remains unchanged. Emerging evidence suggests that HPV/OPSCC is pathologically and molecularly distinct from HPV-negative OPSCC. This review focuses on summarizing treatment strategies for HPV/OPSCC by reviewing the peer-reviewed literature and noting ongoing and planned clinical trials in this disease. We also discuss the potential of designing targeted therapy based on the recent genomic findings of HPV/OPSCC. © 2012 Springer Science+Business Media, LLC. | - |
dc.language | eng | - |
dc.relation.ispartof | Head and Neck Pathology | - |
dc.subject | Chemotherapy | - |
dc.subject | HPV/OPSCC | - |
dc.subject | Radiation | - |
dc.title | Primary Chemotherapy and Radiation as a Treatment Strategy for HPV-Positive Oropharyngeal Cancer | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1007/s12105-012-0364-5 | - |
dc.identifier.pmid | 22782228 | - |
dc.identifier.scopus | eid_2-s2.0-84864138332 | - |
dc.identifier.volume | 6 | - |
dc.identifier.issue | SUPPL. 1 | - |
dc.identifier.spage | 91 | - |
dc.identifier.epage | 97 | - |
dc.identifier.isi | WOS:000214599800011 | - |
dc.identifier.issnl | 1936-055X | - |